Back
Compare AU
Compare CURE vs. JPEQ
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Global X S&P Biotech ETF (CURE) and the Jpmorgan Us 100Q Equity Premium Income Active ETF (JPEQ). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
CURE | JPEQ | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 68 | 8 |
Median incremental investment | $673.61 | $1,750.02 |
Median investment frequency | Monthly | Fortnightly |
Median total investment | $2,062.62 | $15,067.97 |
Average age group | > 35 | > 35 |
Key Summary
CURE | JPEQ | |
|---|---|---|
Strategy | CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index. | JPEQ.AX was created on 2023-05-23 by JPMorgan. The fund's investment portfolio concentrates primarily on total market equity. The investment objective of the Fund is to seek current income while maintaining prospects for capital appreciation. |
Top 3 holdings | Apellis Pharmaceuticals Inc (1.72 %) Revolution Medicines Inc Ordinary Shares (1.57 %) Summit Therapeutics Inc Ordinary Shares (1.52 %) | JPMorgan Nasdaq Equity Premium Inc ETF (99.63 %) |
Top 3 industries | Health Care (100.00 %) Other (10.24 %) | |
Top 3 countries | United States (96.62 %) United Kingdom of Great Britain and Northern Ireland (1.35 %) Switzerland (1.13 %) | United States (96.87 %) Netherlands (1.52 %) Canada (0.81 %) |
Management fee | 0.45 % | 0.4 % |
Key Summary
CURE | JPEQ | |
|---|---|---|
Issuer | Global X | JPMorgan |
Tracking index | S&P Biotechnology Select Industry | |
Asset class | ETF | ETF |
Management fee | 0.45 % | 0.4 % |
Price | $65.48 | $58.29 |
Size | $41.711 million | $80.191 million |
10Y return | N/A | N/A |
Annual distribution yield (5Y) | 5.08 % | 6.22 % |
Market | ASX | ASX |
First listed date | 12/11/2018 | 24/05/2023 |
Purchase fee | $6.50 | $6.50 |
Community Stats
CURE | JPEQ | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 68 | 8 |
Median incremental investment | $673.61 | $1,750.02 |
Median investment frequency | Monthly | Fortnightly |
Median total investment | $2,062.62 | $15,067.97 |
Average age group | > 35 | > 35 |
Pros and Cons
CURE | JPEQ | |
|---|---|---|
Pros |
|
|
Cons |
|
|
CURE | JPEQ |
|---|---|
Lower exposure to US market | Higher exposure to US market |
Higher management fee | Lower management fee |
Higher price growth | Lower price growth |
Lower distribution yield | Higher distribution yield |